To investigate the role of heterogeneous nuclear ribonucleoprotein A2B1 (HNRNPA2B1) in prostate cancer, and to screen the active components of traditional Chinese medicine for targeted treatment of prostate cancer.

The GEPIA, UALCAN, and THPA databases were used to analyze the expression of HNRNPA2B1 in prostate cancer tissues and normal tissues as well as its relationship with the prognosis of prostate cancer. The relationship between HNRNPA2B1 expression and clinical characteristics of prostate cancer patients was also analyzed. The TIMER database was used to analyze the correlation between HNRNPA2B1 expression and immune cell infiltration in prostate cancer. Positively related genes and KEGG pathways of HNRNPA2B1 were analyzed using the LinkedOmics and DAVID databases. The Comparative Toxicogenomics Database (CTD) was used to screen the active components of traditional Chinese medicine that target HNRNPA2B1.

HNRNPA2B1 is highly expressed in prostate cancer, which is related to the prognosis of prostate cancer, lymph node metastasis, and Gleason score. HNRNPA2B1 participates in the immune infiltration of prostate cancer cells. KEGG pathway analysis showed that HNRNPA2B1 and its positively related genes are mainly involved in the spliceosome pathway and the ubiquitin-mediated proteolysis pathway. By searching the CTD, it was found that quercetin, resveratrol, and genistein may be the active components of traditional Chinese medicine targeting HNRNPA2B1.

HNRNPA2B1 is highly expressed in prostate cancer, which is related to the prognosis and immune invasion of prostate cancer. Quercetin, resveratrol, genistein, and other active components of traditional Chinese medicine may play a role in prostate cancer by targeting HNRNPA2B1.